Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)
China · Delayed Price · Currency is CNY 22.10
-0.50 (-2.21%)
At close: Jul 30, 2026
SHE:301089 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 373.85 | 378.34 | 421.69 | 835.51 | 784.72 | 502.48 |
Revenue Growth | -8.90% | -10.28% | -49.53% | 6.47% | 56.17% | -4.82% |
Gross Profit Gross Profit Growth | 74.19 | 81.39 | 112.17 | 470.14 | 455.08 | 188.36 |
Operating Income Operating Income Growth | -88.27 | -84.7 | -41.15 | 299.74 | 307.8 | 83.92 |
Net Income Net Income Growth | -76.61 | -69.66 | -19.88 | 243.07 | 286.54 | 65.71 |
Earnings Per Share EPS Growth | -0.59 | -0.55 | -0.16 | 1.93 | 2.27 | 0.66 |
EPS Growth | - | - | - | -14.98% | 243.94% | -44.54% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
China China Growth | 288.51 | 325 | 751.94 | 699.12 | 343.72 |
Overseas Overseas Growth | 89.84 | 96.69 | 83.57 | 85.6 | 158.77 |
Total Total Growth | 378.34 | 421.69 | 835.51 | 784.72 | 502.48 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 231.23 | 245.41 | 320.11 | 339.26 | 547.25 | 504.84 |
Total Debt Total Debt Growth | 3.28 | 3.25 | 4.22 | - | 40.03 | 69.41 |
Net Cash (Debt) Net Cash Growth | 227.95 | 242.16 | 315.89 | 339.26 | 507.22 | 435.43 |
Net Cash Growth | -17.78% | -23.34% | -6.89% | -33.11% | 16.49% | - |
Net Cash Per Share Net Cash Per Share Growth | 1.76 | 1.91 | 2.54 | 2.69 | 4.02 | 4.37 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 0.41 | -26.19 | 102.67 | 26.95 | 268.85 | 58.19 |
Capital Expenditures CapEx Growth | -40.69 | -44.45 | -83.91 | -185.22 | -148.33 | -112.73 |
Free Cash Flow Free Cash Flow Growth | -40.27 | -70.64 | 18.76 | -158.27 | 120.52 | -54.53 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 19.84% | 21.51% | 26.60% | 56.27% | 57.99% | 37.49% |
Operating Margin | -23.61% | -22.39% | -9.76% | 35.88% | 39.22% | 16.70% |
Pretax Margin | -21.90% | -19.13% | -6.58% | 37.89% | 41.45% | 15.53% |
Profit Margin | -20.49% | -18.41% | -4.71% | 29.09% | 36.51% | 13.08% |
FCF Margin | -10.77% | -18.67% | 4.45% | -18.94% | 15.36% | -10.85% |
| Fiscal Year | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Period Ending | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.250 | 0.400 | 0.100 |
Dividend Per Share Growth | -37.50% | 300.00% | - |
Dividend Yield | 0.47% | 0.56% | 0.13% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 28.12 | 31.66 | 154.17 |
P/FCF Ratio | - | - | 190.19 | - | 75.28 | - |
PS Ratio | 7.65 | 9.37 | 8.46 | 8.18 | 11.56 | 20.16 |